123 results about "Tumor detection" patented technology

The invention provides a tumor real-time tracking and benign and malignant detection method based on a mammary gland ultrasonic video, and the method comprises the steps: collecting the mammary gland ultrasonic video in real time, and inputting the mammary gland ultrasonic video into an UltraNet basic detector to generate a detection result of each frame of ultrasonic image; calculating a similarity probability matrix Si, j to reflect the similarity between the ith target and the jth target; performing cascade matching on the target based on the similarity probability matrix Si, j to form a target track pipeline Ti; and carrying out confidence coefficient updating and bounding box position updating on the detection result in each target track pipeline Ti, and finally outputting a breast lesion detection result of each frame of ultrasonic image. The tumor real-time tracking and benign and malignant detection method based on the breast ultrasonic video has the advantages of high calculation efficiency, high precision and strong robustness, can assist a doctor in accurately positioning a focus and performing diagnosis, and is beneficial to early discovery of breast diseases.

The invention provides a tumor recognition method based on multi-modal feature fusion, relates to the technical field of tumor recognition, and is used for solving the problems of missing multi-modal feature calibration, insufficient semantic association, poor generalization and insufficient clinical interpretability in the prior art. The method comprises the following steps: firstly, synchronously acquiring visual structure and electrical impedance bimodal data through an event-driven sensor array, and completing preprocessing through pulse coding, STDP rule optimization and quality verification; then, respectively extracting structured feature vectors of a tumor visual structure class and characteristic feature vectors of a numerical attribute class by a heterogeneous twin coding engine, and unifying dimensions and distribution through processes such as multi-scale dynamic perception and cross-modal calibration; then based on an attention mechanism, InfoNCE contrast loss and minority class weight gain, dynamic weighted fusion and semantic association enhancement are performed on the bimodal features, and a comprehensive feature vector is generated; and finally, through clinical logic adaptation and multi-center deviation correction, outputting a tumor benign and malignant identification result through a full-connection classifier, and synchronously generating a clinical interpretable report containing key features and weights. According to the method, the complementary advantages of bimodal information are effectively integrated, the problems of heterogeneous multi-center equipment, unbalanced samples and the like are solved, the tumor recognition accuracy and the early-stage tiny tumor detection rate are improved, the computing power consumption is reduced, edge medical equipment deployment is adapted, and the requirements for low misjudgment and traceability of clinical diagnosis are met.

The invention provides a MaskRcnn-based tumor detection method and system, and the method comprises the steps: inputting medical image data into a MaskRcnn network integrated with an edge perception module, generating an edge response graph through a Sobel operator, and enabling the edge response graph to serve as an additional channel injection feature graph, and enhancing the boundary representation; fusing multi-scale features through a feature pyramid network FPN, extracting candidate tumor area features through RoI Align, introducing non-local attention modeling global dependence in the area, extracting directional entropy, texture energy, uniformity and contrast in combination with a gray level co-occurrence matrix GLCM, and splicing to generate structure sensing features; performing classification, bounding box regression and mask segmentation based on the structure perception features, and constructing a joint loss function including classification, regression, mask cross entropy, edge alignment and structure consistency; the positioning capability of the model on the fuzzy tumor contour is effectively improved, the boundary positioning error is remarkably optimized, and the defect that over-segmentation or missing detection is likely to occur in a traditional model is overcome.

This invention relates to the field of data analysis technology, specifically to a cloud-based tumor detection data analysis and sharing system. The invention includes a cloud service platform and multiple local terminals. The local terminals communicate with the cloud service platform via a network and are deployed in various medical institutions. They digitize tumor detection samples to generate raw medical data and extract metadata. The cloud service platform includes a data receiving module for receiving raw data and metadata; a template management module for building and maintaining a feature template library, including a two-stream ensemble classifier; a data calibration module for calling standardized parameter sets from metadata and generating standardized data through a reversible neural network; a data analysis module for analyzing the standardized data; and a data sharing module for responding to requests to share data. The system solves the problem of heterogeneity in multi-center data, improves the model's generalization ability and robustness, and achieves efficient data sharing and accurate analysis.

The invention relates to a radionuclide labeled trimer probe 68Ga-TRAP-(FAPI) 3 targeting FAP and a preparation method thereof, Trap is used as a trivalent chelating platform, and three FAPI targeting units are covalently connected by clicking a chemical linking arm to form a trimer structure; the invention further relates to application of the 68Ga-TRAP-(FAPI) 3 probe in preparation of imaging agents or therapeutic drugs for diagnosing FAP positive diseases, experiments prove that the trimer probe is good in affinity and high in stability, and in cell experiments and animal experiments, the uptake rate of FAP positive cells is kept at a high level within 240 minutes; preclinical and preliminary clinical applications show that the tumor detection rate of the < 68 > Ga-TRAP-FAPI 3 in various cancer models is superior to that of < 18 > F-FDG, and compared with < 68 > Ga-FAPI-04, the < 68 > Ga-TRAP-FAPI 3 is clearer to display focuses (particularly tiny metastases), higher in uptake intensity and particularly outstanding in delayed imaging, and the < 68 > Ga-TRAP-FAPI 3 can be used for preparing a medicine for treating cancer. And a novel drug candidate with better performance is provided for precise diagnosis and staging of tumors and subsequent radionuclide targeted therapy.

The invention relates to a DNA methylation detection method and a reagent. Specifically, the invention relates to a method for diagnosing whether a tumor exists in a subject and whether a tumor postoperative minimal residual focus exists or not by detecting a methylation marker in free DNA in a sample from the subject to judge the methylation level of the DNA, and judging the postoperative prognosis of the subject suffering from the tumor. Methods of predicting postoperative recurrence or assessing the efficacy of a treatment on a subject having a tumor. The invention also relates to a marker, a kit and a detection reagent for the method.

The invention provides a microsatellite site stability detection method and an electronic device thereof. The microsatellite locus stability detection method comprises the following steps: S1) utilizing high-throughput targeted sequencing data of a sample to be detected to obtain feature data in a preset microsatellite locus set, the feature data at least comprising length variation of a short tandem repeat sequence and structural variation occurring at a microsatellite locus; according to the microsatellite stability detection method and device, the problem that in the prior art, a method for detecting microsatellite instability has limitation can be solved, and the microsatellite stability detection method and device are suitable for the field of tumor detection.

The invention provides a digestive tract tumor detection method and system, relates to the field of medical image detection, and solves the technical problem of low accuracy of tumor boundary detection and automatic positioning in a digestive tract tumor image acquisition process in the prior art. The method comprises the following steps: taking a pan-tumor region image as a training sample of a binary decision tree algorithm, constructing an objective function based on the training sample to obtain a first objective function value, and obtaining a depth threshold value and an optimal classification point of the training sample; optimizing the optimal classification point based on the candidate feature sound to obtain a second objective function value; an unknown digestive tract tumor image is accessed, image points of the digestive tract tumor image are marked through a trained binary decision tree algorithm and a regression forest algorithm, the position distribution probability of the image points is generated, a position distribution thermodynamic diagram is generated based on the position distribution probability, and a tumor core area is obtained through mean shift. And completing the separation of the tumor region and the non-tumor region. The application is used in the digestive tract tumor detection process.

The invention discloses a tumor detection device and method based on a diamond quantum sensor, and belongs to the technical field of biomedical detection. The device comprises an optical fiber laser, an optical fiber beam splitter, an optical fiber attenuator, an optical fiber circulator, an optical filter, two photoelectric detectors, a differential amplifier, an electronic filter, a computer, a signal generator, two microwave antennas and an optical fiber probe. The optical fiber probe comprises an optical fiber packaged in a plastic shell, a diamond quantum sensor which is fixed at the tail end of the optical fiber and comprises an NV color center, and a first microwave antenna integrated beside the optical fiber. The laser excites the diamond to generate fluorescence, meanwhile, the signal generator drives the two microwave antennas to apply a microwave field, and the dielectric property of the sample to be detected modulates the fluorescence intensity of the diamond by influencing the microwave field. Laser noise is eliminated through a differential amplification and filtering technology, and fluorescence signal change is analyzed by a computer, so that dielectric constant distribution of a sample is reconstructed, and non-invasive and high-sensitivity detection of tumors is realized.

The invention discloses a nano antibody specifically combined with CD176 protein and application thereof, the nano antibody sequentially comprises a CDR1 region, a CDR2 region and a CDR3 region, the amino acid sequence of the CDR1 region is shown as SEQ ID No.6, the amino acid sequence of the CDR2 region is shown as SEQ ID No.7, and the amino acid sequence of the CDR3 region is shown as SEQ ID No.8. The invention further discloses a preparation method of the nano antibody specifically combined with the CD176 protein and application of the nano antibody specifically combined with the CD176 protein. The invention discovers that the nano antibody with the three complementary determining regions can be combined with CD176 protein (EC50 is 8.617 nM) with high affinity, has the characteristics of small molecular weight, small immunogenicity, better solubility and stability and the like, can effectively detect the expression of CD176 or inhibit the activity of CD176, and has potential value in the aspects of tumor detection and treatment.

The present invention belongs to the technical field of crotonate dyes, and in particular to a near-infrared second-region crotonate dye and its preparation method and application. The near-infrared second-region crotonate dye having a structure shown in Formula 1 provided by the present invention introduces an electron-donating group into the crotonate structure to expand the π conjugation degree of the system, and has a donor-acceptor-donor structure to form a rigid resonant plane structure that stabilizes the zwitterion, effectively regulating the absorption and emission wavelengths of the dye, and red-shifting it to a near-infrared region with a longer wavelength. Thus, the crotonate dye having a structure shown in Formula 1 provided by the present invention has good absorption properties in the near-infrared second region and can be used for photoacoustic imaging of tumor detection; at the same time, it has good fluorescence quantum yield and can be used for fluorescence imaging of tumor detection; and the near-infrared second-region crotonate dye provided by the present invention also has good photothermal conversion efficiency and can be used for photothermal therapy for tumor treatment.

The invention belongs to the technical field of radiography, and particularly relates to a tumor specific imaging probe and a preparation method thereof. The invention provides a novel bimodal imaging probe activated by gamma-glutamyltranspeptidase (GGT). The bimodal imaging probe synergistically integrates the functions of magnetic resonance imaging (MRI) and fluorescence imaging (FI). The probe is meticulously designed, and chiral Gd-DOTA and Cy5 fluorophores are connected to a polymer support through covalent bonds. The molecular structure comprises a GGT responsive part, and selective activation in a tumor microenvironment is ensured, so that the specific targeting ability to tumors is enhanced. Cy5 is a near-infrared fluorescent dye with definite characteristics, and when Cy5 is introduced into the probe, extremely high sensitivity is provided for fluorescence-based tumor molecular level visualization. Due to the high-performance magnetic resonance imaging function and the high-sensitivity fluorescence imaging function, the bimodal probe is endowed with extremely high accuracy in tumor detection and treatment monitoring.

This invention belongs to the field of precision oncology diagnosis and treatment technology, specifically involving a nanomedicine delivery system with tumor microenvironment regulation capabilities, its preparation method, and its application. S1: An organic phase is prepared by dissolving ionizable lipids, helper phospholipids, cholesterol, and functionally modified lipids in a solvent at a molar ratio of 50:38.5:10:1.5. S2: Capsaicin is dissolved in the organic phase obtained in S1, and doxorubicin is dissolved in the solvent to prepare an aqueous phase. The organic and aqueous phases are rapidly mixed in a microfluidic device at a volume ratio of 3:1 to obtain a mixture. S3: The mixture obtained in S2 is placed in a dialysis bag and immersed in Tris buffer for magnetic stirring and dialysis, followed by concentration to obtain (C+D)@LNPPRT. This invention significantly enhances the precision detection of tumors, enables efficient early tumor detection and targeted chemotherapy, and improves treatment efficacy.

The application provides a fluorescence in situ hybridization image breakage and fusion collaborative determination method and device and medium, in order to solve the problems of FISH image breakage and fusion detection fragmentation, insufficient robustness and high misjudgment rate, after separating the cell image channel, the application calculates a binary threshold value based on an adaptive extreme value ratio, combines a connected domain median area filter to extract independent fluorescent points and an equivalent diameter, generates a cell nucleus mask based on fusion morphology and appearance characteristics, performs two-way collaborative determination, globally determines that heterochromatic fluorescent points with a distance less than a fusion threshold value are fused and physically removed, and then connects the remaining points in the same cell nucleus by using a global optimal pairing algorithm, and determines that the breakage threshold value based on the equivalent diameter is greater than the distance dynamically set, and finally outputs a comprehensive classification state. The application is used for precise determination of tumor FISH detection.

The invention discloses a tumor detection marker and application thereof in medicine preparation, and belongs to the technical field of biomedicine. Clinical sample qRT-PCR (quantitative real-time polymerase chain reaction) shows that ENST00000412203.1 is obviously up-regulated in breast cancer tissues, the area (AUC) under the ROC curve reaches 0.9822, and the diagnosis efficiency is excellent. In addition, the invention further finds that the expression of the polypeptide in lymph node metastasis tissues is obviously improved, and metastasis specificity is displayed. Meanwhile, the expression of ENST00000412203.1 is knocked down through siRNA, it is found that proliferation, migration and invasion of breast cancer cells are remarkably inhibited, and therefore the siRNA can be used for preparing targeted therapy drugs for breast cancer and has important clinical application value.

Provided herein are methods for measuring concentration of circulating cell free DNA (cfDNA) from a sample of a subject, for the purposes of cancer or tumor detection and / or characterization.

We disclose a composition, comprising a compound, comprising a melanin precursor that spontaneously synthesizes a melanin when in free form in vivo, and a peptide directly covalently bonded to or indirectly linked to the melanin precursor, wherein the direct covalent bond or indirect link of the peptide to the melanin precursor blocks spontaneous synthesis of the melanin in vivo in the absence of protease activity. We also disclose methods of tumor imaging, tumor detection, diagnosis, and treatment, including methods comprising administering, to a patient suffering from a tumor, the composition; and either surgically resecting the tumor or thermally ablating the tumor, wherein the surgical resection is guided at least in part by contrast imparted by, or the thermally ablating targets cells containing, the melanin, wherein the melanin is spontaneously synthesized in the tumor after administering the composition.

Provided herein is a method for detecting a tumour that can be applied to cell-free samples, to cell-free detect circulating tumour DNA. The method utilizes detection of adjacent methylation signals within a single sequencing read as the basic positive tumour signal, thereby decreasing false positives. The method comprises extracting DNA from a cell-free sample obtained from a subject, bisulphite converting the DNA, amplifying regions methylated in cancer (CpG islands, CpG shores, and / or CpG shelves), generating sequencing reads, and detecting tumour signals. To increase sensitivity, biased primers designed based on bisulphite converted methylated sequences can be used. Target methylated regions can be selected from a pre-validated set according to the specific aim of the test. Absolute number, proportion, and / or distribution of tumour signals may be used for tumour detection or classification. The method is also useful in, predicting, prognosticating, and / or monitoring response to treatment, tumour load, relapse, cancer development, or risk.

This invention belongs to the field of tumor detection and relates to a dynamic evaluation method for the efficacy of Bragg therapy driven by multi-cycle, multimodal peripheral blood data. The method includes the following steps: acquiring peripheral blood multimodal data from patients participating in Bragg therapy, and dividing the peripheral blood multimodal data into a training dataset and a validation dataset; constructing a Bragg therapy efficacy evaluation model using the training dataset, and validating the Bragg therapy efficacy evaluation model using the validation dataset; receiving peripheral blood multimodal data from patients participating in Bragg therapy, and calculating the evaluation results using the Bragg therapy efficacy evaluation model. This invention, by combining long short-term memory networks and graph neural networks, can effectively track the temporal changes of immune cell characteristics, thereby providing a more accurate basis for developing personalized treatment plans for Bragg therapy patients, improving treatment outcomes and survival rates.

This invention provides a tumor lesion region detection system and method based on an ultrasound patch assembly, belonging to the field of ultrasound medical imaging technology. The system includes an ultrasound patch assembly for attaching to the detection area and acquiring characteristic parameters such as left-right symmetry, curvature distribution, and edge perturbation; a preprocessing module that adaptively selects a bi-symmetric, five-point centering, or three-point centering scanning mode based on the characteristic parameters; a scanning control module that dynamically activates the phased array and sets scanning path parameters for ultrasound signal acquisition; a signal processing module that processes the signals to obtain ultrasound images; and an analysis module that segments the image and identifies lesions based on a pre-trained medical image segmentation model, completing tumor boundary delineation and structure extraction. This system can intelligently adjust the scanning mode for different detection areas, improving the accuracy and adaptability of tumor detection.

The present application relates to the field of tumor detection, and in particular to a biological sample analysis method and system based on nuclear pore distribution patterns. The method provided by the present application comprises: S101, obtaining microscopic image data of a biological sample; S102, obtaining a first region of interest, a second region of interest and a third region of interest; S103, drawing a nuclear membrane edge curve; S104, extracting nuclear pore distribution-nuclear membrane curvature distribution data of cells in the biological sample; S105, identifying the nuclear pore distribution pattern of the cells in the biological sample; S106, evaluating the state of the tissue or organ corresponding to the biological sample. Based on the identified nuclear pore distribution pattern of individual cells in the biological sample, the present application can evaluate the state of the tissue or organ corresponding to the biological sample according to the overall nuclear pore distribution pattern of the cells in the biological sample, such as whether it is a tumor sample, whether it has a tendency to cancer, etc., which is of great significance for early diagnosis of tumors.

Disclosed is a compound having the following structure: TIFF2023537627000024.tif61169X is an anion (e.g., a biologically relevant anion such as chloride, iodide, etc.); Y is NH, NR 10 , or CR 11 R 12 where Z is a heteroatom (e.g., O, S, or Se), and R and R 1 are independently selected from methyl, ethyl, propyl (e.g., n-propyl, isopropyl), butyl (e.g., n-butyl, isobutyl, tert-butyl), and the like, and combinations thereof. In various examples, R and R 1 At least one of the atoms is not an oxygen atom (both cannot be oxygen atoms to form -NO2). 2 and R 3 R is independently selected from methyl, ethyl, propyl (e.g., n-propyl, isopropyl), butyl (e.g., n-butyl, isobutyl, tert-butyl), etc., and combinations thereof. 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 are independently selected from hydrogen, alkyl groups (e.g., methyl, ethyl, propyl (e.g., n-propyl, isopropyl), butyl (e.g., n-butyl, isobutyl, tert-butyl), etc.), and combinations thereof. Also disclosed are compositions and methods of using the compounds and compositions. The compounds or compositions can be used to visualize or identify tumors.

Described herein are methods and compositions related to using genomic and / or methylation-based TF from a genomic, epigenomic detection platform to predict clinical benefit to therapies, including through evaluation of real-world patients. Tumor detection, methylation-based tumor fraction, and methylation-based molecular response are prognostic and predictive of outcomes, Prolonged treatment of patients not deriving benefit risks increased toxicity, may reduce chance of success for targeted treatments, and may increase clonal hematopoietic burden, wherein methylation based detection largely eliminates noise in determining genomic molecular response (gMR), thereby demonstrating advantageous use of methylation based molecular response (mMR).

The application provides a microsatellite site stability detection method and an electronic device thereof. The microsatellite site stability detection method comprises the following steps: S1, obtaining characteristic data in a preset microsatellite site set by using high-throughput targeted sequencing data of a to-be-detected sample, wherein the characteristic data at least comprises the following: length variation of a short tandem repeat sequence and structural variation occurring at the microsatellite site; S2, establishing a prediction model by using the characteristic data; and S3, outputting a microsatellite stability result of the to-be-detected sample by using the prediction model. The method can solve the limitation problem of the microsatellite instability detection method in the prior art and is suitable for the tumor detection field.

The invention belongs to the technical field of tumor detection, and particularly relates to a probe composition for nasopharyngeal carcinoma MRD detection, a kit and application, the probe composition for nasopharyngeal carcinoma MRD detection comprises the following probes, the sequences of the probes are SEQ IN NO.1-106; according to the targeted probe capture technology, the probe is designed according to the whole genome sequence of the EB virus, so that all EB virus sequences in a sample are captured, and the detection sensitivity and reliability are improved.

The application relates to a multifunctional contrast agent for capturing plasma cell free DNA and a preparation method and application thereof, the preparation method of the multifunctional contrast agent comprises the following steps: S1, activating a contrast agent surface carboxyl; S2, modifying a DNA binding protein on the contrast agent surface; and S3, sealing unreacted sites on the contrast agent surface. Compared with the prior art, the multifunctional contrast agent prepared by the application has good biocompatibility, not only has an imaging examination function, but also can be applied to capturing cell free DNA in circulating blood, and is further applied to tumor detection and tumor prognosis monitoring.

This invention provides a method, system, and device for constructing a 3D-printed liver model based on image data, comprising: acquiring CT and MRI image data of an individual patient; performing multimodal image segmentation on the CT and MRI image data to obtain structural segmentation images; fusing the structural segmentation images to obtain a liver and tumor anatomical structure model; performing three-dimensional reconstruction on the liver and tumor anatomical structure model to obtain a target three-dimensional visualization model; and 3D printing the target three-dimensional visualization model. This application integrates CT and MRI imaging modalities to obtain more comprehensive and accurate liver anatomical information. CT provides clear images of the liver parenchyma and blood vessels, while MRI provides more sensitive soft tissue contrast and tumor detection. The combination of the two can compensate for the shortcomings of a single imaging technology, improving the realism and information content of the model.

The invention provides a parotid gland tumor processing method and device based on multi-modal medical data, and can relate to the artificial intelligence technology, and the method comprises the steps: obtaining a parotid gland tumor detection image of a patient; obtaining parotid gland tumor related problems of the text mode of the related patient; inputting the parotid tumor detection image into an image description model to obtain description information of the parotid tumor detection image; and inputting the description information serving as prompt information and parotid gland tumor related questions into a large language model to obtain parotid gland tumor related answers. The image description model and the large language model are both single-mode models, the training data of the image description model and the training data of the large language model can be easily obtained through an open source community at present, and the manual annotation cost is low when the large language model is finely adjusted, so that a serial large model architecture formed by the two models can be applied to parotid tumor treatment scenes, and the method is suitable for popularization and application. Furthermore, parotid gland tumor related answers, such as parotid gland tumor diagnosis or treatment schemes, can be given based on the multi-modal medical data.

The invention discloses a kit for detecting circulating tumor DNA (deoxyribonucleic acid) of portal vein and branch vein blood of portal vein. The kit comprises: a nucleic acid extraction assembly comprising an optimized lysate and selectively bound magnetic beads; the library construction component comprises a terminal repair / tailing fusion enzyme and a Y-shaped linker with a molecular identifier; the targeted enrichment assembly comprises a specific primer group and a probe group and is used for enriching related gene targets of the abdominal organ tumors; and necessary reaction components. Through an optimized nucleic acid extraction method, an efficient library construction system and a precise targeted enrichment technology, high-sensitivity detection of low-abundance ctDNA in portal venous blood is achieved, and the lower detection limit reaches 0.1% of mutation allele frequency. The kit is particularly suitable for early diagnosis, curative effect monitoring and prognosis evaluation of abdominal organ tumors such as intestinal cancer, liver cancer and pancreatic cancer.

The application discloses a tumor detection device and method based on a diamond quantum sensor, and belongs to the technical field of biomedical detection. The device comprises a fiber laser, a fiber beam splitter, a fiber attenuator, a fiber ring, a filter, two photodetectors, a differential amplifier, an electronic filter, a computer, a signal generator, two microwave antennas and a fiber probe. The fiber probe comprises a fiber packaged in a plastic shell, a diamond quantum sensor containing NV color centers fixed at the end of the fiber, and a first microwave antenna integrated beside the fiber. The laser excites the diamond to generate fluorescence, and the signal generator drives the two microwave antennas to apply a microwave field. The dielectric properties of the sample to be measured will modulate the fluorescence intensity of the diamond by affecting the microwave field. The laser noise is eliminated through differential amplification and filtering technology, and the computer analyzes the fluorescence signal change to reconstruct the dielectric constant distribution of the sample, realizing non-invasive and high-sensitivity detection of tumors.